NeoGenomics, Inc. (NEO) Stock Grade

About NeoGenomics, Inc.'s fundamentals

NeoGenomics is a medical diagnostics company with a market capitalization of $301.3 million that generated 10.1% year-over-year revenue growth. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -14.9%, which means it spent approximately 15 cents more than it earned on every dollar of revenue. The company does not pay a dividend, and standard profitability metrics like P/E ratio and return on equity are not applicable given the loss position. Investors should note that while the company is growing its top line, it has not yet achieved profitability at the bottom line.